<a href="https://www.fiercebiotech.com/medtech/medtronic-inks-650m-deal-spr-therapeutics" hreflang="en">Medtronic inks $650M deal for SPR Therapeutics </a>
Medtronic has announced a $650 million acquisition of SPR Therapeutics, which offers a minimally invasive SPRINT Peripheral Nerve Stimulation System for chronic pain management, enhancing Medtronic's pain therapy portfolio. This acquisition aims to provide patients with a temporary, non-surgical alternative to traditional spinal cord stimulation, addressing a growing need for nonpharmacological pain relief options.
Medtronic's acquisition of SPR Therapeutics for $650 million highlights a strategic expansion into minimally invasive pain management solutions. This move addresses a significant market gap by offering a temporary, non-surgical alternative for chronic pain relief, which is increasingly important given the opioid crisis and rising demand for nonpharmacological treatments. For those tracking investment signals, this deal underscores a growth opportunity in the peripheral nerve stimulation market, expected to expand at 5% to 11% annually through the early 2030s.